首頁 > 市場調查報告書 > 製藥

癌症生物標記

市場調查報告書

商品編碼

1540801

2024-2032 年按分析技術、生物分子、癌症類型、應用、最終用戶和地區分類的癌症生物標記市場報告

Cancer Biomarkers Market Report by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region 2024-2032

出版日期: 2024年08月10日 | 出版商:

IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

IMARC Group年全球癌症生物標記市場規模達279億美元。個人化醫療的進步，基因組學、蛋白質組學和生物資訊學等技術的重大創新，對伴隨診斷的需求增加以及人口老化的加劇是推動市場的一些主要因素。

癌症生物標記是可以在體內發現的特定分子或物質，並提供有關癌症的存在、進展或特徵的有價值的資訊。這些生物標記在腫瘤學領域中發揮著至關重要的作用，有助於各種癌症的早期檢測、診斷、治療監測和預後。它們通常存在於血液、尿液、組織或其他體液中。癌症生物標記的鑑定和分析涉及基因組學、蛋白質組學和代謝組學等先進技術。這些技術使研究人員和醫療保健專業人員能夠檢測分子層面的細微變化，從而深入了解癌症的發展及其對治療的反應。透過測量特定生物標記的水平，臨床醫生可以為個別患者量身定做治療計劃，從而實現更有針對性的治療並改善結果。

全球各種癌症盛行率的不斷上升是一個重要的促進因素。隨著癌症病例數量的增加，對生物標記等準確的早期診斷工具的需求不斷增加。此外，生物標記提供非侵入性的癌症檢測和監測方法，減少患者不適並實現頻繁評估。這種便利性推動了患者的接受度和臨床採用。除此之外，早期發現對於提高存活率至關重要。癌症生物標記可以在癌症的最早階段進行檢測，從而實現及時干預和潛在的治癒性治療。除此之外，對伴隨診斷的需求正在促進生物標記市場的成長，伴隨診斷有助於確定對患者最有效的治療方法。與此一致的是，全球老化人口更容易罹患癌症。這種人口趨勢推動了對改進診斷和治療方法的需求，其中生物標記發揮關鍵作用。此外，基因組學、蛋白質組學和生物資訊學等技術的快速進步徹底改變了癌症生物標記的發現和分析。這些技術能夠以更高的靈敏度和特異性鑑定新型生物標記。此外，向個人化醫療的轉變增加了對生物標記的需求，因為它們能夠識別每個患者癌症特有的特定遺傳、分子和蛋白質組特徵，促進標靶治療並改善治療結果。

癌症生物標記市場趨勢/促進因素：

全球癌症盛行率不斷上升，為市場創造了積極的前景。生物標記廣泛用於早期癌症檢測以及治療和管理過程中，以準確可靠地預測結果。與此一致的是，由於污染水平上升、吸煙趨勢和不良飲食習慣導致肺癌發病率不斷增加，從而促進了市場的成長。此外，遺傳生物標記發現的各種技術進步，例如次世代定序（NGS）、聚合酶鍊式反應（PCR）、基因表現譜（微陣列）和人工不雅（AI）有助於預測癌症復發後的復發。此外，醫療保健專業人員和患者對早期診斷重要性的認知不斷提高，以及由於缺乏標準診斷而導致癌症治療向個人化醫療的重大轉變，有利於市場成長。其他因素，包括醫療保健行業的顯著成長、廣泛的研發 (R&D) 活動以及加強藥物開發流程的各種政府舉措的實施，預計將推動市場成長。

癌症發生率上升

世界衛生組織 (WHO) 報告稱，由於生活方式改變、環境暴露和人口老化等因素，癌症病例負擔不斷增加。這種激增需要改進診斷工具，以便在治療最有效的最早期階段檢測出癌症。癌症生物標記能夠識別細微的分子變化，從而實現早期檢測和風險評估。這使得醫療保健專業人員能夠制定量身定做的治療計劃，最佳化患者的治療結果。隨著癌症盛行率持續上升，對生物標記等準確、高效的診斷解決方案的需求預計將保持上升趨勢。

個人化醫療的進步

每種癌症都是獨特的，由獨特的遺傳和分子特徵驅動。這種複雜性需要量身定做的治療方法來解決個別癌症的特定屬性。生物標記為了解這些錯綜複雜的問題提供了一個窗口，使臨床醫生能夠選擇針對驅動疾病的精確分子改變的療法。透過最大限度地減少治療選擇中的反覆試驗，個人化醫療可以提高治療效果，同時減少不良反應。由於可以快速分析患者遺傳和分子特徵的先進技術的出現，這種方法受到了關注。隨著個人化醫療日益受到重視，對指導治療決策的生物標記的需求將持續成長。

重大技術創新

新一代定序、質譜和微陣列分析等高通量技術的出現大大提高了我們識別和分析潛在生物標記的能力。這些方法能夠辨識出指示不同癌症類型的特定基因突變、表觀遺傳學變化和蛋白質表現模式。此外，生物資訊學工具有助於解釋大量資料集，有助於發現新的候選生物標記。這些技術進步不僅加快了生物標記的發現，還提高了其敏感性和特異性，使它們在臨床使用中更加可靠。隨著技術的不斷發展，預計經過驗證的癌症生物標記庫將會擴大，進一步塑造癌症診斷和治療的模式。

市場結構
關鍵參與者
關鍵參與者簡介
- Abbott Laboratories
- Agilent Technologies Inc.
- Becton Dickinson and Company
- bioMerieux SA
- Danaher Corporation
- F. Hoffmann-La Roche AG
- General Electric Company
- Illumina Inc.
- Qiagen NV
- Sino Biological Inc.
- Thermo Fisher Scientific Inc.

簡介目錄圖表

Product Code: SR112024A5834

The global cancer biomarkers market size reached US$ 27.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 77.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.7% during 2024-2032.The rising cancer incidences, advancements in personalized medicine, significant innovations in technologies such as genomics, proteomics, and bioinformatics, augmenting demand for companion diagnostics, and increasing aging population some of the major factors propelling the market.

Cancer biomarkers are specific molecules or substances that can be found in the body and provide valuable information about the presence, progression, or characteristics of cancer. These biomarkers play a crucial role in the field of oncology by aiding in the early detection, diagnosis, treatment monitoring, and prognosis of various types of cancer. They are typically present in blood, urine, tissues, or other bodily fluids. The identification and analysis of cancer biomarkers involve advanced techniques such as genomics, proteomics, and metabolomics. These techniques enable researchers and healthcare professionals to detect subtle changes at the molecular level, which can provide insights into the development of cancer and its response to treatments. By measuring the levels of specific biomarkers, clinicians can tailor treatment plans to individual patients, leading to more targeted therapies and improved outcomes.

The increasing prevalence of various types of cancers across the globe is a significant driver. As the number of cancer cases grows, the demand for accurate and early diagnostic tools, like biomarkers, intensifies. Additionally, biomarkers offer non-invasive methods of cancer detection and monitoring, reducing patient discomfort and enabling frequent assessments. This convenience is driving both patient acceptance and clinical adoption. Other than this, early detection is crucial for improving survival rates. Cancer biomarkers allow for the detection of cancers at their earliest stages, enabling timely intervention and potentially curative treatments. Besides this, the demand for companion diagnostics, which help determine the most effective treatment for a patient, is fostering the growth of the biomarkers market. In line with this, the global aging population is more susceptible to cancer. This demographic trend is driving the need for improved diagnostic and therapeutic approaches, in which biomarkers play a pivotal role. Furthermore, rapid advancements in technologies such as genomics, proteomics, and bioinformatics have revolutionized cancer biomarker discovery and analysis. These technologies enable the identification of novel biomarkers with higher sensitivity and specificity. Moreover, the shift toward personalized medicine has escalated the demand for biomarkers as they enable the identification of specific genetic, molecular, and proteomic signatures unique to each patient's cancer, facilitating targeted therapies and improving treatment outcomes.

Cancer Biomarkers Market Trends/Drivers:

The increasing prevalence of cancer across the globe is creating a positive outlook for the market. Biomarkers are widely used for early cancer detection and during treatment and management to accurately and reliably predict outcomes. In line with this, the increasing incidences of lung cancer due to the upsurge in pollution levels, smoking trends and poor ingestion habits is augmenting the market growth. Moreover, various technological advancements in genetic biomarker discovery, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), gene expression profiling (microarray), and the artificial inelegance (AI) that assist in predicting the recurrence of cancer after treatment, are providing an impetus to the market growth. Additionally, the increasing awareness amongst healthcare professionals and patients about the importance of early diagnosis and the significant shift toward personalized medicine for cancer treatment due to the lack of standard diagnosis is favoring the market growth. Other factors, including the significant growth in the healthcare industry, extensive research and development (R&D) activities and the implementation of various government initiatives for enhancing the drug development processes, are anticipated to drive the market toward growth.

Rising Cancer Incidence

The World Health Organization (WHO) reports a growing burden of cancer cases, attributed to factors such as lifestyle changes, environmental exposures, and an aging population. This surge necessitates improved diagnostic tools that can detect cancer at its earliest stages, when treatment is most effective. Cancer biomarkers, with their ability to identify subtle molecular changes, enable early detection and risk assessment. This empowers healthcare professionals to devise tailored treatment plans, optimizing patient outcomes. As cancer prevalence continues to escalate, the demand for accurate and efficient diagnostic solutions like biomarkers is expected to remain on an upward trajectory.

Advancements in Personalized Medicine

Each cancer is unique, driven by distinct genetic and molecular characteristics. This complexity demands tailored treatment approaches that address the specific attributes of an individual's cancer. Biomarkers offer a window into these intricacies, allowing clinicians to select therapies that target the precise molecular alterations driving the disease. By minimizing trial and error in treatment selection, personalized medicine enhances treatment efficacy while reducing adverse effects. This approach has gained traction due to the availability of advanced technologies that can rapidly analyze a patient's genetic and molecular profile. As personalized medicine gains prominence, the demand for biomarkers that guide treatment decisions will continue to grow.

Significant Technological Innovations

The advent of high-throughput techniques such as next-generation sequencing, mass spectrometry, and microarray analysis has exponentially increased our ability to identify and analyze potential biomarkers. These methods enable the identification of specific genetic mutations, epigenetic changes, and protein expression patterns that are indicative of different cancer types. Moreover, bioinformatics tools facilitate the interpretation of vast datasets, aiding in the discovery of novel biomarker candidates. These technological advancements not only expedite biomarker discovery but also enhance their sensitivity and specificity, making them more reliable for clinical use. As technology continues to evolve, it is anticipated that the pool of validated cancer biomarkers will expand, further shaping the landscape of cancer diagnosis and treatment.

Cancer Biomarkers Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global cancer biomarkers market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on profiling technology, biomolecule, cancer type, application, and end user.

Breakup by Profiling Technology:

Omic Technologies

Imaging Technologies

Immunoassays

Cytogenetics

The report has provided a detailed breakup and analysis of the market based on the profiling technology. This includes omic technologies, imaging technologies, immunoassays, and cytogenetics.

Omic technologies, encompassing genomics, proteomics, and metabolomics, play a pivotal role in cancer biomarker discovery and profiling. Genomic analysis reveals alterations in DNA sequences, identifying mutations and genetic variations associated with cancer development. Proteomics delves into the intricate world of proteins, identifying biomarkers by studying their expression levels, modifications, and interactions. Metabolomics focuses on small molecule metabolites, shedding light on metabolic pathways disrupted in cancer. These omic approaches provide a comprehensive understanding of the molecular intricacies underlying cancer, enabling the identification of potential biomarkers with high precision. Their ability to uncover subtle changes in genes, proteins, and metabolites makes omic technologies indispensable in the quest for reliable cancer biomarkers, enhancing diagnostic accuracy and paving the way for targeted therapies.

Techniques like positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) provide detailed anatomical and functional information. These technologies enable the visualization of tumors, their growth patterns, and interactions with surrounding tissues. Molecular imaging techniques, a subset of imaging technologies, utilize specific tracers to visualize molecular changes within tumors. This aids in identifying unique biomarkers expressed on cancer cells. Imaging-based biomarker profiling not only aids in accurate diagnosis but also assists in treatment planning and monitoring. As imaging technologies continue to advance, their role in non-invasive biomarker identification and real-time monitoring of treatment responses becomes increasingly integral.

Enzyme-linked immunosorbent assays (ELISA) and multiplex immunoassays measure the concentration of specific proteins, including biomarkers indicative of various cancers. Their high sensitivity and ability to analyze multiple analytes simultaneously make immunoassays invaluable in cancer diagnosis, prognosis, and therapeutic monitoring. Immunoassays are particularly well-suited for measuring soluble proteins and antigens present in blood or other bodily fluids. The advent of novel immunoassay platforms, such as bead-based and microfluidic systems, further enhances their capabilities. Immunoassay-based biomarker profiling not only aids in clinical decision-making but also expedites the development of targeted therapies by identifying patients likely to respond favorably to specific treatments.

Breakup by Biomolecule:

Genetic Biomarkers

Protein Biomarkers

Glyco-Biomarkers

Genetic biomarkers hold the largest share in the market

A detailed breakup and analysis of the market based on the biomolecule has also been provided in the report. This includes genetic biomarkers, protein biomarkers, and glycol-biomarkers. According to the report, genetic biomarkers accounted for the largest market share.

Genetic biomarkers offer insights into an individual's genetic predisposition, mutations, and variations that contribute to disease development. The advent of advanced genomic sequencing technologies has revolutionized our ability to decode the genetic code, identifying specific gene alterations associated with various cancers. Genetic biomarkers not only facilitate early cancer detection but also guide personalized treatment strategies. By pinpointing genetic mutations driving a particular cancer, clinicians can tailor therapies to target these specific genetic anomalies, thereby enhancing treatment efficacy while minimizing adverse effects. Moreover, genetic biomarkers play a crucial role in the development of precision medicine, where treatments are tailored to a patient's genetic profile.

Breakup by Cancer Type:

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Stomach Cancer

Others

Lung cancer dominates the market

The report has provided a detailed breakup and analysis of the market based on the cancer type. This includes breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, and others. According to the report, lung cancer represented the largest segment.

Lung cancer holds a significant global prevalence, ranking among the leading causes of cancer-related deaths. The strong association between lung cancer and smoking, along with environmental factors, contributes to its widespread occurrence. Furthermore, advancements in diagnostic technologies, including imaging and molecular profiling, have improved lung cancer detection and classification. This has led to a higher number of diagnosed cases, contributing to the segment's prominence. Additionally, the complex nature of lung cancer, characterized by diverse subtypes like non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), necessitates targeted therapies based on biomarker profiles. This drives research and innovation, fostering the development of precision medicine approaches tailored to specific lung cancer subtypes.

Breakup by Application:

Diagnostics

Prognostics

Risk Assessment

Drug Discovery and Development

Others

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes diagnostics, prognostics, risk assessment, drug discovery and development, and others.

Cancer biomarkers play a critical role in enabling early and accurate cancer detection. By identifying specific molecular signatures associated with various cancer types, biomarkers assist in pinpointing the presence of cancer at its initial stages. This facilitates timely intervention, ultimately leading to improved patient outcomes. Biomarker-based diagnostics encompass a range of techniques, including blood tests, imaging, and molecular assays, which collectively contribute to effective and non-invasive cancer detection.

By analyzing specific biomarkers, clinicians can gauge the aggressiveness of the cancer, assess the risk of recurrence, and estimate patient survival rates. These insights guide treatment planning, allowing for tailored therapies that match the anticipated disease trajectory. Prognostic biomarkers contribute to informed decision-making, enabling patients and healthcare providers to make choices aligned with individual prognosis.

These biomarkers enable early screening of individuals at elevated risk due to genetic, environmental, or lifestyle factors. By identifying those at risk, healthcare professionals can implement targeted surveillance, preventive measures, and lifestyle interventions to reduce the likelihood of cancer development. Risk management based on biomarkers empowers proactive healthcare strategies that emphasize prevention and early intervention.

Breakup by End User:

Hospitals

Academic and Research Institutions

Ambulatory Surgical Centers

Diagnostic Laboratories

Others

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, academic and research institutions, ambulatory surgical centers, diagnostic laboratories, and others.

With their comprehensive range of medical services and infrastructure, hospitals serve as essential hubs for cancer diagnosis, treatment, and management. Biomarker-based tests are seamlessly integrated into hospital workflows, facilitating timely and accurate cancer diagnosis. Hospitals also offer the necessary facilities for patient monitoring and follow-up, making them central to cancer care. The demand for biomarkers in hospitals is driven by the need for efficient diagnostic tools that aid in early detection, prognosis, and treatment decision-making.

These institutions conduct in-depth research to identify and validate novel biomarkers, contributing to the expansion of our understanding of cancer biology. They also develop cutting-edge technologies and methodologies for biomarker discovery and analysis. Academic institutions serve as platforms for training the next generation of researchers, clinicians, and professionals who will drive biomarker-related research and applications. Additionally, academic collaborations often lead to the development of innovative diagnostic and therapeutic approaches, further enriching the biomarkers market.

These centers provide outpatient surgical and medical procedures, including cancer diagnostics and treatment. ASCs offer efficient and convenient options for patients who require biomarker-based tests, minimizing the need for hospitalization. They cater to patients seeking specialized care in a more streamlined and patient-centered environment. As the trend towards outpatient care continues to grow, ambulatory surgical centers are increasingly adopting biomarker-based diagnostic and treatment methods, contributing to their significance within the market ecosystem.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for cancer biomarkers.

North America possesses a well-established healthcare infrastructure with advanced medical facilities, research centers, and academic institutions. This provides a conducive environment for the integration of biomarker-based diagnostics and treatments into clinical practice. Additionally, substantial investments in cancer research and healthcare technology contribute to the continuous advancement of biomarker discovery and validation. This, coupled with a strong emphasis on personalized medicine, drives the demand for biomarker-driven approaches in patient care. Moreover, North America's proactive regulatory landscape, with agencies like the FDA, fosters the validation and approval of new biomarkers, ensuring their safety and efficacy. This regulatory support instills confidence among healthcare professionals and encourages the adoption of biomarker-based tests. Besides this, a higher awareness of cancer prevention, early detection, and treatment options within the population further fuels the demand for biomarker-based solutions. The presence of a substantial patient pool and a robust pharmaceutical industry also play a pivotal role in the region's dominance in the cancer biomarkers market.

Competitive Landscape:

Major players invest heavily in R&D to identify and validate new biomarkers. This involves extensive laboratory research, clinical trials, and collaborations with academic institutions to discover biomarkers that offer higher accuracy and specificity in cancer detection and monitoring. Additionally, collaboration between biotechnology firms, pharmaceutical companies, research institutions, and healthcare providers accelerates the translation of biomarker discoveries into practical applications. Partnerships facilitate the development of novel diagnostics and therapies that incorporate biomarker information. Other than this, key players continually innovate by adopting and developing cutting-edge technologies, such as next-generation sequencing, liquid biopsies, and advanced imaging techniques. These innovations enhance biomarker detection sensitivity, allowing for earlier and more accurate cancer diagnoses. Besides this, leading firms are focusing on developing companion diagnostics that identify patients most likely to respond to specific treatments. This approach optimizes treatment selection, leading to better patient outcomes and reduced healthcare costs. In line with this, key market players are driving the shift toward personalized medicine by utilizing biomarker information to tailor treatments to individual patients. This approach improves treatment efficacy and minimizes adverse effects. Furthermore, collaboration with regulatory authorities, such as the FDA, ensures that biomarker-based tests meet rigorous standards for accuracy and safety. Regulatory approvals enhance trust in these tests among healthcare professionals and patients.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

Agilent Technologies Inc.

Becton Dickinson and Company

bioMerieux SA

Danaher Corporation

F. Hoffmann-La Roche AG

General Electric Company

Illumina Inc.

Qiagen N.V.

Sino Biological Inc.

Thermo Fisher Scientific Inc.

Recent Developments:

Thermos Fisher Scientific Inc. has recently entered into a significant companion diagnostic agreement with Chugai Pharmaceutical Co. Ltd. This collaboration holds strategic importance within the pharmaceutical and diagnostic sectors. Through this agreement, both companies aim to combine their expertise to enhance the development and availability of companion diagnostics. Thermo Fisher's prowess in cutting-edge scientific solutions and Chugai Pharmaceutical's extensive experience in pharmaceuticals complement each other, fostering the creation of advanced diagnostic tools.

Agilent Technologies Inc. introduced a noteworthy initiative in the form of a Biomarker Pathologist Training Program. This program is a significant step in the field of pathology and biomarker research. Through this endeavor, Agilent is taking a leadership role in promoting education and skill development within the domain of biomarker analysis.

Illumina Inc. embarked on a significant collaborative endeavor by forming a co-development partnership with SomaLogic. This partnership represents a pivotal moment in the landscape of biomarker research and clinical advancements. Illumina, renowned for its pioneering work in next-generation sequencing (NGS), has joined forces with SomaLogic, a distinguished name in the realm of protein biomarker discovery.

Key Questions Answered in This Report

1. What was the size of the global cancer biomarkers market in 2023?
2. What is the expected growth rate of the global cancer biomarkers market during 2024-2032?
3. What are the key factors driving the global cancer biomarkers market?
4. What has been the impact of COVID-19 on the global cancer biomarkers market?
5. What is the breakup of the global cancer biomarkers market based on the biomolecule?
6. What is the breakup of the global cancer biomarkers market based on the cancer type?
7. What are the key regions in the global cancer biomarkers market?
8. Who are the key players/companies in the global cancer biomarkers market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Cancer Biomarkers Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Profiling Technology

6.1 Omic Technologies
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Imaging Technologies
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Immunoassays
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Cytogenetics
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Biomolecule

7.1 Genetic Biomarkers
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Protein Biomarkers
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Glyco-Biomarkers
- 7.3.1 Market Trends
- 7.3.2 Market Forecast

8 Market Breakup by Cancer Type

8.1 Breast Cancer
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Lung Cancer
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Colorectal Cancer
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Prostate Cancer
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Stomach Cancer
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast

9 Market Breakup by Application

9.1 Diagnostics
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Prognostics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Risk Assessment
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Drug Discovery and Development
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast

10 Market Breakup by End User

10.1 Hospitals
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Academic and Research Institutions
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Ambulatory Surgical Centers
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
10.4 Diagnostic Laboratories
- 10.4.1 Market Trends
- 10.4.2 Market Forecast
10.5 Others
- 10.5.1 Market Trends
- 10.5.2 Market Forecast

11 Market Breakup by Region

11.1 North America
- 11.1.1 United States
  - 11.1.1.1 Market Trends
  - 11.1.1.2 Market Forecast
- 11.1.2 Canada
  - 11.1.2.1 Market Trends
  - 11.1.2.2 Market Forecast
11.2 Asia-Pacific
- 11.2.1 China
  - 11.2.1.1 Market Trends
  - 11.2.1.2 Market Forecast
- 11.2.2 Japan
  - 11.2.2.1 Market Trends
  - 11.2.2.2 Market Forecast
- 11.2.3 India
  - 11.2.3.1 Market Trends
  - 11.2.3.2 Market Forecast
- 11.2.4 South Korea
  - 11.2.4.1 Market Trends
  - 11.2.4.2 Market Forecast
- 11.2.5 Australia
  - 11.2.5.1 Market Trends
  - 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
  - 11.2.6.1 Market Trends
  - 11.2.6.2 Market Forecast
- 11.2.7 Others
  - 11.2.7.1 Market Trends
  - 11.2.7.2 Market Forecast
11.3 Europe
- 11.3.1 Germany
  - 11.3.1.1 Market Trends
  - 11.3.1.2 Market Forecast
- 11.3.2 France
  - 11.3.2.1 Market Trends
  - 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
  - 11.3.3.1 Market Trends
  - 11.3.3.2 Market Forecast
- 11.3.4 Italy
  - 11.3.4.1 Market Trends
  - 11.3.4.2 Market Forecast
- 11.3.5 Spain
  - 11.3.5.1 Market Trends
  - 11.3.5.2 Market Forecast
- 11.3.6 Russia
  - 11.3.6.1 Market Trends
  - 11.3.6.2 Market Forecast
- 11.3.7 Others
  - 11.3.7.1 Market Trends
  - 11.3.7.2 Market Forecast
11.4 Latin America
- 11.4.1 Brazil
  - 11.4.1.1 Market Trends
  - 11.4.1.2 Market Forecast
- 11.4.2 Mexico
  - 11.4.2.1 Market Trends
  - 11.4.2.2 Market Forecast
- 11.4.3 Others
  - 11.4.3.1 Market Trends
  - 11.4.3.2 Market Forecast
11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast

12 SWOT Analysis

12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
- 16.3.1 Abbott Laboratories
  - 16.3.1.1 Company Overview
  - 16.3.1.2 Product Portfolio
  - 16.3.1.3 Financials
  - 16.3.1.4 SWOT Analysis
- 16.3.2 Agilent Technologies Inc.
  - 16.3.2.1 Company Overview
  - 16.3.2.2 Product Portfolio
  - 16.3.2.3 Financials
  - 16.3.2.4 SWOT Analysis
- 16.3.3 Becton Dickinson and Company
  - 16.3.3.1 Company Overview
  - 16.3.3.2 Product Portfolio
  - 16.3.3.3 Financials
  - 16.3.3.4 SWOT Analysis
- 16.3.4 bioMerieux SA
  - 16.3.4.1 Company Overview
  - 16.3.4.2 Product Portfolio
  - 16.3.4.3 Financials
  - 16.3.4.4 SWOT Analysis
- 16.3.5 Danaher Corporation
  - 16.3.5.1 Company Overview
  - 16.3.5.2 Product Portfolio
  - 16.3.5.3 Financials
  - 16.3.5.4 SWOT Analysis
- 16.3.6 F. Hoffmann-La Roche AG
  - 16.3.6.1 Company Overview
  - 16.3.6.2 Product Portfolio
  - 16.3.6.3 SWOT Analysis
- 16.3.7 General Electric Company
  - 16.3.7.1 Company Overview
  - 16.3.7.2 Product Portfolio
  - 16.3.7.3 Financials
  - 16.3.7.4 SWOT Analysis
- 16.3.8 Illumina Inc.
  - 16.3.8.1 Company Overview
  - 16.3.8.2 Product Portfolio
  - 16.3.8.3 Financials
  - 16.3.8.4 SWOT Analysis
- 16.3.9 Qiagen N.V.
  - 16.3.9.1 Company Overview
  - 16.3.9.2 Product Portfolio
  - 16.3.9.3 Financials
  - 16.3.9.4 SWOT Analysis
- 16.3.10 Sino Biological Inc.
  - 16.3.10.1 Company Overview
  - 16.3.10.2 Product Portfolio
- 16.3.11 Thermo Fisher Scientific Inc.
  - 16.3.11.1 Company Overview
  - 16.3.11.2 Product Portfolio
  - 16.3.11.3 Financials
  - 16.3.11.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Cancer Biomarkers Market: Major Drivers and Challenges
Figure 2: Global: Cancer Biomarkers Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Cancer Biomarkers Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Cancer Biomarkers Market: Breakup by Profiling Technology (in %), 2023
Figure 5: Global: Cancer Biomarkers Market: Breakup by Biomolecule (in %), 2023
Figure 6: Global: Cancer Biomarkers Market: Breakup by Cancer Type (in %), 2023
Figure 7: Global: Cancer Biomarkers Market: Breakup by Application (in %), 2023
Figure 8: Global: Cancer Biomarkers Market: Breakup by End User (in %), 2023
Figure 9: Global: Cancer Biomarkers Market: Breakup by Region (in %), 2023
Figure 10: Global: Cancer Biomarkers (Omic Technologies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Cancer Biomarkers (Omic Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Cancer Biomarkers (Imaging Technologies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Cancer Biomarkers (Imaging Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Cancer Biomarkers (Immunoassays) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Cancer Biomarkers (Immunoassays) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Cancer Biomarkers (Cytogenetics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Cancer Biomarkers (Cytogenetics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Cancer Biomarkers (Genetic Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Cancer Biomarkers (Genetic Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Cancer Biomarkers (Protein Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Cancer Biomarkers (Protein Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Cancer Biomarkers (Glyco-Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Cancer Biomarkers (Glyco-Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Cancer Biomarkers (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Cancer Biomarkers (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Cancer Biomarkers (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Cancer Biomarkers (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Cancer Biomarkers (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Cancer Biomarkers (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Cancer Biomarkers (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Cancer Biomarkers (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Cancer Biomarkers (Stomach Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Cancer Biomarkers (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Cancer Biomarkers (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Cancer Biomarkers (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Cancer Biomarkers (Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Cancer Biomarkers (Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Cancer Biomarkers (Prognostics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Cancer Biomarkers (Prognostics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Global: Cancer Biomarkers (Risk Assessment) Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Global: Cancer Biomarkers (Risk Assessment) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Global: Cancer Biomarkers (Drug Discovery and Development) Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Global: Cancer Biomarkers (Drug Discovery and Development) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Global: Cancer Biomarkers (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Global: Cancer Biomarkers (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Global: Cancer Biomarkers (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Global: Cancer Biomarkers (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Global: Cancer Biomarkers (Academic and Research Institutions) Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Global: Cancer Biomarkers (Academic and Research Institutions) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Global: Cancer Biomarkers (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Global: Cancer Biomarkers (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Global: Cancer Biomarkers (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Global: Cancer Biomarkers (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Global: Cancer Biomarkers (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Global: Cancer Biomarkers (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: North America: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: North America: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: United States: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: United States: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Canada: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Canada: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Asia-Pacific: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Asia-Pacific: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: China: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: China: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Japan: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Japan: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: India: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: India: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: South Korea: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: South Korea: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Australia: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Australia: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Indonesia: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Indonesia: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Others: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Europe: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Europe: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Germany: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Germany: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: France: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: France: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: United Kingdom: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 85: United Kingdom: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 86: Italy: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 87: Italy: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 88: Spain: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 89: Spain: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 90: Russia: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 91: Russia: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 92: Others: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 93: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 94: Latin America: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 95: Latin America: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 96: Brazil: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 97: Brazil: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 98: Mexico: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 99: Mexico: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 100: Others: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 101: Others: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 102: Middle East and Africa: Cancer Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
Figure 103: Middle East and Africa: Cancer Biomarkers Market: Breakup by Country (in %), 2023
Figure 104: Middle East and Africa: Cancer Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 105: Global: Cancer Biomarkers Industry: SWOT Analysis
Figure 106: Global: Cancer Biomarkers Industry: Value Chain Analysis
Figure 107: Global: Cancer Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Cancer Biomarkers Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Cancer Biomarkers Market Forecast: Breakup by Profiling Technology (in Million US$), 2024-2032
Table 3: Global: Cancer Biomarkers Market Forecast: Breakup by Biomolecule (in Million US$), 2024-2032
Table 4: Global: Cancer Biomarkers Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
Table 5: Global: Cancer Biomarkers Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 6: Global: Cancer Biomarkers Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 7: Global: Cancer Biomarkers Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 8: Global: Cancer Biomarkers Market: Competitive Structure
Table 9: Global: Cancer Biomarkers Market: Key Players

02-2729-4219

+886-2-2729-4219